Details of the Drug Combination

General Information of Drug Combination (ID: DCMFIQ0)

• Drug Combination Name: Miconazole + Mifepristone
• Indication: Hepatoblastoma; Status: Investigative [1]
• Component Drugs:
  Miconazole (DMPMYE8): Small molecular drug
  Mifepristone (DMGZQEF): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: HB3
  Zero Interaction Potency (ZIP) Score: 11.859
  Bliss Independence Score: 15.115
  Loewe Additivity Score: 2.668
  LHighest Single Agent (HSA) Score: 7.905

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Miconazole

Disease Entry	ICD 11	Status	REF
Cutaneous candidiasis	1F23.14	Approved	[2]
Fungal infection	1F29-1F2F	Approved	[3]
Mycoses	1F2Z	Approved	[2]
Onychomycosis	EE12.1	Approved	[2]
Tinea corporis	1F28.Y	Approved	[2]
Tinea cruris	1F28.3	Approved	[2]
Tinea versicolor	1F2D.0	Approved	[2]
Tinea pedis	1F28.2	Investigative	[2]

Miconazole Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Candida Cytochrome P450 51 (Candi ERG11)	TTTSOUD	CP51_CANAL	Modulator	[5]

Miconazole Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[6]

Miconazole Interacts with 17 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[7]
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Decreases Activity	[8]
Aromatase (CYP19A1)	OTZ6XF74	CP19A_HUMAN	Decreases Activity	[9]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Decreases Expression	[10]
Tyrosine aminotransferase (TAT)	OT2CJ91O	ATTY_HUMAN	Decreases Expression	[10]
Nuclear receptor subfamily 1 group I member 3 (NR1I3)	OTS3SGH7	NR1I3_HUMAN	Decreases Expression	[10]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Decreases Activity	[11]
Adenylate cyclase type 9 (ADCY9)	OT1IZT5K	ADCY9_HUMAN	Increases Activity	[12]
Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)	OTZKVLVJ	CP17A_HUMAN	Decreases Activity	[13]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Decreases Expression	[14]
Interleukin-5 (IL5)	OTAFPSCO	IL5_HUMAN	Decreases Expression	[14]
Cathepsin D (CTSD)	OTQZ36F3	CATD_HUMAN	Increases Expression	[15]
RAC-alpha serine/threonine-protein kinase (AKT1)	OT8H2YY7	AKT1_HUMAN	Decreases Phosphorylation	[15]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Decreases Activity	[16]
Sequestosome-1 (SQSTM1)	OTGY5D5J	SQSTM_HUMAN	Increases Expression	[15]
Microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B)	OTUYHB84	MLP3B_HUMAN	Increases Lipidation	[15]
Lanosterol 14-alpha demethylase (CYP51A1)	OTAYHG9C	CP51A_HUMAN	Decreases Response To Substance	[17]

Indication(s) of Mifepristone

Disease Entry	ICD 11	Status	REF
Cushing disease	5A70	Approved	[4]

Mifepristone Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Modulator	[20]

Mifepristone Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[21]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[22]

Mifepristone Interacts with 228 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[23]
Pro-neuropeptide Y (NPY)	OT4ICV3P	NPY_HUMAN	Increases ADR	[24]
Nuclear receptor subfamily 1 group I member 3 (NR1I3)	OTS3SGH7	NR1I3_HUMAN	Increases Expression	[10]
Frizzled-9 (FZD9)	OTTZ9MKK	FZD9_HUMAN	Increases Expression	[18]
Forkhead box protein N3 (FOXN3)	OTOJYJZP	FOXN3_HUMAN	Increases Expression	[18]
Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2)	OTKOZRZP	PLOD2_HUMAN	Increases Expression	[18]
Actin-binding LIM protein 1 (ABLIM1)	OTHXEK3E	ABLM1_HUMAN	Increases Expression	[18]
Ectoderm-neural cortex protein 1 (ENC1)	OTJEUB6U	ENC1_HUMAN	Increases Expression	[18]
Histone-lysine N-methyltransferase 2D (KMT2D)	OTTVHCLY	KMT2D_HUMAN	Decreases Expression	[18]
17-beta-hydroxysteroid dehydrogenase type 6 (HSD17B6)	OTSB55D2	H17B6_HUMAN	Decreases Expression	[18]
Branched-chain-amino-acid aminotransferase, mitochondrial (BCAT2)	OT8L6EGI	BCAT2_HUMAN	Decreases Expression	[18]
Calpain-5 (CAPN5)	OTQ8QM7K	CAN5_HUMAN	Decreases Expression	[18]
Leucine-rich repeat transmembrane protein FLRT2 (FLRT2)	OTGD8TID	FLRT2_HUMAN	Decreases Expression	[18]
Septin-4 (SEPTIN4)	OTD16B30	SEPT4_HUMAN	Decreases Expression	[18]
Cationic amino acid transporter 4 (SLC7A4)	OTAVC6QS	CTR4_HUMAN	Decreases Expression	[18]
Proline dehydrogenase 1, mitochondrial (PRODH)	OT7SQ1C7	PROD_HUMAN	Decreases Expression	[18]
Synaptogyrin-1 (SYNGR1)	OT0MBUK5	SNG1_HUMAN	Decreases Expression	[18]
C-X-C motif chemokine 13 (CXCL13)	OT2AT4N8	CXL13_HUMAN	Decreases Expression	[18]
Frizzled-6 (FZD6)	OTBCPII8	FZD6_HUMAN	Increases Expression	[18]
Sushi repeat-containing protein SRPX2 (SRPX2)	OT6A63TX	SRPX2_HUMAN	Increases Expression	[18]
Sorting nexin-2 (SNX2)	OT889MQA	SNX2_HUMAN	Increases Expression	[18]
P antigen family member 4 (PAGE4)	OT2VLWT0	PAGE4_HUMAN	Decreases Expression	[18]
Slit homolog 3 protein (SLIT3)	OTU8MKEU	SLIT3_HUMAN	Decreases Expression	[18]
Large neutral amino acids transporter small subunit 3 (SLC43A1)	OTQJQY3S	LAT3_HUMAN	Decreases Expression	[18]
Solute carrier family 22 member 3 (SLC22A3)	OTQYGVXX	S22A3_HUMAN	Decreases Expression	[18]
E3 ubiquitin-protein ligase NEURL1 (NEURL1)	OT2C4P70	NEUL1_HUMAN	Increases Expression	[18]
Cystatin-F (CST7)	OTQWZUVQ	CYTF_HUMAN	Decreases Expression	[18]
Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3 (B3GAT3)	OTDSN5XF	B3GA3_HUMAN	Decreases Expression	[18]
Myelin protein zero-like protein 1 (MPZL1)	OTJSUUHR	MPZL1_HUMAN	Decreases Expression	[18]
Supervillin (SVIL)	OTWQQ1WK	SVIL_HUMAN	Increases Expression	[18]
Follistatin-related protein 3 (FSTL3)	OT75489W	FSTL3_HUMAN	Decreases Expression	[18]
Protein LDOC1 (LDOC1)	OTWZH4O9	LDOC1_HUMAN	Decreases Expression	[18]
Coagulation factor XIII A chain (F13A1)	OTO8O184	F13A_HUMAN	Increases Expression	[18]
Tissue-type plasminogen activator (PLAT)	OTQPDNAB	TPA_HUMAN	Increases Expression	[18]
Myc proto-oncogene protein (MYC)	OTPV5LUK	MYC_HUMAN	Decreases Expression	[18]
Prolactin (PRL)	OTWFQGX7	PRL_HUMAN	Increases Expression	[18]
Collagen alpha-1(II) chain (COL2A1)	OT5E59C8	CO2A1_HUMAN	Decreases Expression	[18]
Apolipoprotein C-I (APOC1)	OTA58CED	APOC1_HUMAN	Decreases Expression	[18]
Annexin A1 (ANXA1)	OT5OFDJC	ANXA1_HUMAN	Increases Expression	[18]
Plasminogen activator inhibitor 1 (SERPINE1)	OTT0MPQ3	PAI1_HUMAN	Decreases Expression	[18]
Cyclin-dependent kinase 1 (CDK1)	OTW1SC2N	CDK1_HUMAN	Increases Expression	[18]
Protein S100-A6 (S100A6)	OTHHPZQ8	S10A6_HUMAN	Decreases Expression	[18]
Tyrosine 3-monooxygenase (TH)	OT6ZORKP	TY3H_HUMAN	Decreases Expression	[18]
Decorin (DCN)	OTWLJL7K	PGS2_HUMAN	Increases Expression	[18]
Thrombospondin-1 (THBS1)	OT0ECWK3	TSP1_HUMAN	Increases Expression	[18]
Stromelysin-1 (MMP3)	OTGBI74Z	MMP3_HUMAN	Increases Expression	[18]
Glutathione S-transferase A1 (GSTA1)	OTA7K5XA	GSTA1_HUMAN	Increases Expression	[18]
Inhibin beta A chain (INHBA)	OTSP64PQ	INHBA_HUMAN	Increases Expression	[18]
Matrilysin (MMP7)	OTVT3SEJ	MMP7_HUMAN	Increases Expression	[18]
Stromelysin-2 (MMP10)	OTJDWW8Q	MMP10_HUMAN	Increases Expression	[18]
Growth-regulated alpha protein (CXCL1)	OT3WCTZV	GROA_HUMAN	Decreases Expression	[18]
Fructose-bisphosphate aldolase C (ALDOC)	OTEC13I5	ALDOC_HUMAN	Decreases Expression	[18]
Glutathione S-transferase theta-2 (GSTT2)	OTANW3TJ	GST2_HUMAN	Decreases Expression	[18]
C-C motif chemokine 3 (CCL3)	OTW2H3ND	CCL3_HUMAN	Decreases Expression	[18]
Thyroid hormone receptor alpha (THRA)	OTKRLVD7	THA_HUMAN	Decreases Expression	[18]
Thyroid hormone receptor beta (THRB)	OTBBIRHZ	THB_HUMAN	Increases Expression	[18]
Pyruvate carboxylase, mitochondrial (PC)	OT6O0V51	PYC_HUMAN	Decreases Expression	[18]
Creatine kinase B-type (CKB)	OTUCKOTT	KCRB_HUMAN	Decreases Expression	[18]
Cadherin-1 (CDH1)	OTFJMXPM	CADH1_HUMAN	Increases Expression	[18]
Cytochrome P450 4B1 (CYP4B1)	OTJP46CB	CP4B1_HUMAN	Decreases Expression	[18]
Retinoic acid receptor gamma (RARG)	OT8LHMDH	RARG_HUMAN	Decreases Expression	[18]
HLA class II histocompatibility antigen, DO beta chain (HLA-DOB)	OTKADDUB	DOB_HUMAN	Decreases Expression	[18]
Aminopeptidase N (ANPEP)	OTP3WYFD	AMPN_HUMAN	Decreases Expression	[18]
15-hydroxyprostaglandin dehydrogenase (HPGD)	OTYZI6JB	PGDH_HUMAN	Decreases Expression	[18]
NAD(P)H dehydrogenase 1 (NQO1)	OTZGGIVK	NQO1_HUMAN	Decreases Expression	[18]
Platelet glycoprotein 4 (CD36)	OT5CZWKY	CD36_HUMAN	Decreases Expression	[18]
Fumarylacetoacetase (FAH)	OTGZA1YR	FAAA_HUMAN	Decreases Expression	[18]
Gap junction alpha-1 protein (GJA1)	OTT94MKL	CXA1_HUMAN	Increases Expression	[18]
Insulin-like growth factor-binding protein 3 (IGFBP3)	OTIX63TX	IBP3_HUMAN	Increases Expression	[18]
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A)	OT2D9DOV	TNR1A_HUMAN	Increases Expression	[18]
Fibulin-1 (FBLN1)	OT5MHHOP	FBLN1_HUMAN	Decreases Expression	[18]
Prostaglandin G/H synthase 1 (PTGS1)	OTHCRLEC	PGH1_HUMAN	Decreases Expression	[18]
Integrin alpha-6 (ITGA6)	OT3FA39C	ITA6_HUMAN	Increases Expression	[18]
Laminin subunit alpha-2 (LAMA2)	OTFROQWE	LAMA2_HUMAN	Decreases Expression	[18]
Endothelin receptor type B (EDNRB)	OTLLZV3P	EDNRB_HUMAN	Increases Expression	[18]
Insulin-like growth factor-binding protein 5 (IGFBP5)	OTRE5V0C	IBP5_HUMAN	Decreases Expression	[18]
Atypical chemokine receptor 3 (ACKR3)	OTA6GA4F	ACKR3_HUMAN	Decreases Expression	[18]
Collagen alpha-5(IV) chain (COL4A5)	OTHG60RE	CO4A5_HUMAN	Decreases Expression	[18]
ER lumen protein-retaining receptor 2 (KDELR2)	OT9QW7Q0	ERD22_HUMAN	Increases Expression	[18]
Catenin beta-1 (CTNNB1)	OTZ932A3	CTNB1_HUMAN	Increases Expression	[18]
Pigment epithelium-derived factor (SERPINF1)	OTWZH98J	PEDF_HUMAN	Decreases Expression	[18]
Prostaglandin-H2 D-isomerase (PTGDS)	OT71NN7C	PTGDS_HUMAN	Decreases Expression	[18]
5-hydroxytryptamine receptor 2B (HTR2B)	OTM1AD9J	5HT2B_HUMAN	Increases Expression	[18]
Glutamate receptor 1 (GRIA1)	OT85LOCJ	GRIA1_HUMAN	Decreases Expression	[18]
C-X-C motif chemokine 5 (CXCL5)	OTZOUPCA	CXCL5_HUMAN	Increases Expression	[18]
Prostacyclin receptor (PTGIR)	OTWTABYM	PI2R_HUMAN	Increases Expression	[18]
Small ribosomal subunit protein eS10 (RPS10)	OTE3VSAH	RS10_HUMAN	Increases Expression	[18]
Microtubule-associated protein 1B (MAP1B)	OTVXW089	MAP1B_HUMAN	Increases Expression	[18]
Stromal cell-derived factor 1 (CXCL12)	OT2QX5LL	SDF1_HUMAN	Increases Expression	[18]
Transcription factor SOX-9 (SOX9)	OTVDJFGN	SOX9_HUMAN	Increases Expression	[18]
Heat shock 70 kDa protein 13 (HSPA13)	OTYXMC4G	HSP13_HUMAN	Increases Expression	[18]
DNA polymerase delta subunit 2 (POLD2)	OTBNASP6	DPOD2_HUMAN	Decreases Expression	[18]
MARCKS-related protein (MARCKSL1)	OT13J2FM	MRP_HUMAN	Increases Expression	[18]
Steroidogenic acute regulatory protein, mitochondrial (STAR)	OTFEZ5AI	STAR_HUMAN	Decreases Expression	[18]
ADP-ribosylation factor-like protein 4D (ARL4D)	OTG5I3KU	ARL4D_HUMAN	Decreases Expression	[18]
Matrix metalloproteinase-14 (MMP14)	OT9C197Z	MMP14_HUMAN	Increases Expression	[18]
Matrix metalloproteinase-16 (MMP16)	OTSFQ2BJ	MMP16_HUMAN	Increases Expression	[18]
RNA-binding protein Nova-1 (NOVA1)	OT6A9KHY	NOVA1_HUMAN	Increases Expression	[18]
Lumican (LUM)	OTSRC874	LUM_HUMAN	Increases Expression	[18]
ATP-citrate synthase (ACLY)	OTRL9ZRP	ACLY_HUMAN	Increases Expression	[18]
Cadherin-11 (CDH11)	OTIZKPTF	CAD11_HUMAN	Increases Expression	[18]
BH3-interacting domain death agonist (BID)	OTOSHSHU	BID_HUMAN	Increases Expression	[18]
Sestrin-3 (SESN3)	OTJRY1Y5	SESN3_HUMAN	Increases Expression	[18]
Actin, cytoplasmic 1 (ACTB)	OT1MCP2F	ACTB_HUMAN	Decreases Expression	[18]
Ras-related protein Rap-1b (RAP1B)	OTHEIIMM	RAP1B_HUMAN	Increases Expression	[18]
26S proteasome regulatory subunit 10B (PSMC6)	OTG8997V	PRS10_HUMAN	Increases Expression	[18]
Large ribosomal subunit protein eL39 (RPL39)	OTL8TZHQ	RL39_HUMAN	Increases Expression	[18]
Contactin-associated protein 1 (CNTNAP1)	OT5Y03EU	CNTP1_HUMAN	Decreases Expression	[18]
Fractalkine (CX3CL1)	OTPLGI0E	X3CL1_HUMAN	Increases Expression	[18]
Sushi repeat-containing protein SRPX (SRPX)	OT5B9LXS	SRPX_HUMAN	Decreases Expression	[18]
C-C motif chemokine 8 (CCL8)	OTCTWYN8	CCL8_HUMAN	Decreases Expression	[18]
Rho-related GTP-binding protein RhoG (RHOG)	OTJ7J1WA	RHOG_HUMAN	Decreases Expression	[18]
Small EDRK-rich factor 2 (SERF2)	OTZQDYCZ	SERF2_HUMAN	Increases Expression	[18]
Norrin (NDP)	OTGDJ4US	NDP_HUMAN	Decreases Expression	[18]
Angiopoietin-1 receptor (TEK)	OT78YN57	TIE2_HUMAN	Increases Expression	[18]
Tyrosine-protein kinase BTK (BTK)	OTG3CDVK	BTK_HUMAN	Increases Expression	[18]
Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit alpha (PPP2R3A)	OTSK5GFC	P2R3A_HUMAN	Increases Expression	[18]
Early activation antigen CD69 (CD69)	OTGJHSVP	CD69_HUMAN	Increases Expression	[18]
Tight junction protein ZO-1 (TJP1)	OTBDCUPK	ZO1_HUMAN	Increases Expression	[18]
Sperm-associated antigen 1 (SPAG1)	OT29JZKW	SPAG1_HUMAN	Increases Expression	[18]
ATP-binding cassette sub-family C member 8 (ABCC8)	OTCWQ54I	ABCC8_HUMAN	Decreases Expression	[18]
Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 (AIMP1)	OTTA5C3U	AIMP1_HUMAN	Increases Expression	[18]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 2 (BNIP2)	OTVZD4H6	BNIP2_HUMAN	Increases Expression	[18]
Metastasis-associated protein MTA1 (MTA1)	OTBHW3S9	MTA1_HUMAN	Decreases Expression	[18]
Phospholipase D1 (PLD1)	OTMVUKW6	PLD1_HUMAN	Increases Expression	[18]
Laminin subunit gamma-2 (LAMC2)	OTJMTM72	LAMC2_HUMAN	Increases Expression	[18]
Collagen alpha-6(IV) chain (COL4A6)	OTUREU5Z	CO4A6_HUMAN	Decreases Expression	[18]
Interleukin-13 receptor subunit alpha-2 (IL13RA2)	OTPC2G0X	I13R2_HUMAN	Increases Expression	[18]
ADP-ribosylation factor-like protein 6-interacting protein 1 (ARL6IP1)	OT536XAV	AR6P1_HUMAN	Increases Expression	[18]
Receptor-type tyrosine-protein phosphatase kappa (PTPRK)	OTAP5AT3	PTPRK_HUMAN	Increases Expression	[18]
P2Y purinoceptor 14 (P2RY14)	OTDGZKED	P2Y14_HUMAN	Increases Expression	[18]
Monocyte to macrophage differentiation factor (MMD)	OTB5I4OC	PAQRB_HUMAN	Increases Expression	[18]
TSC22 domain family protein 1 (TSC22D1)	OTN4GFWD	T22D1_HUMAN	Increases Expression	[18]
Adipogenesis regulatory factor (ADIRF)	OTTJP8D4	ADIRF_HUMAN	Decreases Expression	[18]
Mitogen-activated protein kinase 6 (MAPK6)	OTDDNF3Q	MK06_HUMAN	Increases Expression	[18]
Laminin subunit alpha-3 (LAMA3)	OTFME7HT	LAMA3_HUMAN	Decreases Expression	[18]
Centrosomal protein kizuna (KIZ)	OT5VCKSM	KIZ_HUMAN	Increases Expression	[18]
Carboxypeptidase Z (CPZ)	OT5HUR28	CBPZ_HUMAN	Increases Expression	[18]
F-box only protein 46 (FBXO46)	OT773EPG	FBX46_HUMAN	Decreases Expression	[18]
Plexin domain-containing protein 2 (PLXDC2)	OTS1FUV6	PXDC2_HUMAN	Increases Expression	[18]
Acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase (B3GNT6)	OTAX8BNJ	B3GN6_HUMAN	Decreases Expression	[18]
Protein mono-ADP-ribosyltransferase TIPARP (TIPARP)	OTZ4BG4B	PARPT_HUMAN	Decreases Expression	[18]
Kinesin-like protein KIF27 (KIF27)	OTV70I2Q	KIF27_HUMAN	Increases Expression	[18]
Osteopetrosis-associated transmembrane protein 1 (OSTM1)	OTKNJDH7	OSTM1_HUMAN	Increases Expression	[18]
Membrane progestin receptor alpha (PAQR7)	OTIWX5AM	PAQR7_HUMAN	Decreases Expression	[18]
Secreted frizzled-related protein 1 (SFRP1)	OT0U9G41	SFRP1_HUMAN	Increases Expression	[18]
RB1-inducible coiled-coil protein 1 (RB1CC1)	OTZK8PFX	RBCC1_HUMAN	Increases Expression	[18]
Protein phosphatase 1 regulatory subunit 1C (PPP1R1C)	OTVH6BND	PPR1C_HUMAN	Increases Expression	[18]
Kelch-like protein 6 (KLHL6)	OTLDECOX	KLHL6_HUMAN	Increases Expression	[18]
C-type lectin domain family 2 member B (CLEC2B)	OT0W0M0L	CLC2B_HUMAN	Increases Expression	[18]
(3R)-3-hydroxyacyl-CoA dehydrogenase (HSD17B8)	OTX1DWEF	DHB8_HUMAN	Decreases Expression	[18]
Tribbles homolog 2 (TRIB2)	OTHSX3MX	TRIB2_HUMAN	Increases Expression	[18]
Histone deacetylase 2 (HDAC2)	OTUYVFKN	HDAC2_HUMAN	Increases Expression	[18]
Type II iodothyronine deiodinase (DIO2)	OTGPNSLH	IOD2_HUMAN	Increases Expression	[18]
Stathmin-2 (STMN2)	OT0FUHLH	STMN2_HUMAN	Increases Expression	[18]
Seipin (BSCL2)	OT73V6Y4	BSCL2_HUMAN	Decreases Expression	[18]
Receptor expression-enhancing protein 6 (REEP6)	OTY4FPO8	REEP6_HUMAN	Decreases Expression	[18]
Mannose-1-phosphate guanyltransferase alpha (GMPPA)	OTADC03N	GMPPA_HUMAN	Decreases Expression	[18]
Mastermind-like protein 3 (MAML3)	OTZFV53Z	MAML3_HUMAN	Increases Expression	[18]
Translocation protein SEC62 (SEC62)	OTCWEL5F	SEC62_HUMAN	Increases Expression	[18]
Mitochondrial import inner membrane translocase subunit Tim17-A (TIMM17A)	OTVFRL8G	TI17A_HUMAN	Increases Expression	[18]
C-C motif chemokine 13 (CCL13)	OTNX0JD0	CCL13_HUMAN	Decreases Expression	[18]
SH3-containing GRB2-like protein 3-interacting protein 1 (SGIP1)	OTQW6R3Z	SGIP1_HUMAN	Increases Expression	[18]
Receptor expression-enhancing protein 2 (REEP2)	OTPCRA5O	REEP2_HUMAN	Decreases Expression	[18]
Latexin (LXN)	OTZQ2M6Y	LXN_HUMAN	Increases Expression	[18]
Complement C1q tumor necrosis factor-related protein 6 (C1QTNF6)	OT57EPQC	C1QT6_HUMAN	Increases Expression	[18]
Cysteine-rich secretory protein LCCL domain-containing 2 (CRISPLD2)	OTVSFHTL	CRLD2_HUMAN	Decreases Expression	[18]
E3 ubiquitin-protein ligase SMURF2 (SMURF2)	OT3TRVL7	SMUF2_HUMAN	Increases Expression	[18]
Netrin-4 (NTN4)	OTDRRMP3	NET4_HUMAN	Increases Expression	[18]
Endothelial cell-specific molecule 1 (ESM1)	OT331Y8V	ESM1_HUMAN	Increases Expression	[18]
Exosome complex component RRP46 (EXOSC5)	OTADUQ7H	EXOS5_HUMAN	Decreases Expression	[18]
Protein reprimo (RPRM)	OTNNBAS1	RPRM_HUMAN	Decreases Expression	[18]
E3 ubiquitin-protein ligase RNF146 (RNF146)	OTE4CO7E	RN146_HUMAN	Increases Expression	[18]
DNA damage-inducible transcript 4 protein (DDIT4)	OTHY8SY4	DDIT4_HUMAN	Decreases Expression	[18]
CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6)	OT70T27A	CKLF6_HUMAN	Increases Expression	[18]
Ankyrin repeat domain-containing protein 10 (ANKRD10)	OTIZ2VK8	ANR10_HUMAN	Increases Expression	[18]
LIM and cysteine-rich domains protein 1 (LMCD1)	OT3AWE8O	LMCD1_HUMAN	Decreases Expression	[18]
Sentrin-specific protease 1 (SENP1)	OTO8J4VV	SENP1_HUMAN	Increases Expression	[18]
Phosphatidylethanolamine N-methyltransferase (PEMT)	OTKXRUL9	PEMT_HUMAN	Decreases Expression	[18]
DnaJ homolog subfamily B member 9 (DNAJB9)	OT38EQT6	DNJB9_HUMAN	Increases Expression	[18]
Alpha-catulin (CTNNAL1)	OTESJ6JD	CTNL1_HUMAN	Increases Expression	[18]
Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2 (ST6GALNAC2)	OT9PBQVT	SIA7B_HUMAN	Increases Expression	[18]
Polypyrimidine tract-binding protein 2 (PTBP2)	OTF4S7NE	PTBP2_HUMAN	Increases Expression	[18]
Frizzled-4 (FZD4)	OTGLZIE0	FZD4_HUMAN	Increases Expression	[18]
Frizzled-10 (FZD10)	OTSAENLT	FZD10_HUMAN	Increases Expression	[18]
Lysosomal thioesterase PPT2 (PPT2)	OTD5VJ9A	PPT2_HUMAN	Increases Expression	[18]
Sorting nexin-12 (SNX12)	OTARRSWB	SNX12_HUMAN	Decreases Expression	[18]
HIG1 domain family member 1A, mitochondrial (HIGD1A)	OTS351DV	HIG1A_HUMAN	Increases Expression	[18]
Band 4.1-like protein 3 (EPB41L3)	OTS6CHG2	E41L3_HUMAN	Increases Expression	[18]
Long-chain fatty acid transport protein 5 (SLC27A5)	OT4OK511	S27A5_HUMAN	Decreases Expression	[18]
Axin-2 (AXIN2)	OTRMGQNU	AXIN2_HUMAN	Increases Expression	[18]
Cytosolic Fe-S cluster assembly factor NUBP2 (NUBP2)	OTYOTM2B	NUBP2_HUMAN	Increases Expression	[18]
Adhesion G-protein coupled receptor G1 (ADGRG1)	OTQBB8NT	AGRG1_HUMAN	Decreases Expression	[18]
Calcineurin-binding protein cabin-1 (CABIN1)	OT4G5CIK	CABIN_HUMAN	Increases Expression	[18]
SEC23-interacting protein (SEC23IP)	OTTZ0FXP	S23IP_HUMAN	Increases Expression	[18]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2)	OTHF4H9U	DHI2_HUMAN	Increases Expression	[25]
Nitric oxide synthase 3 (NOS3)	OTLDT7NR	NOS3_HUMAN	Decreases Expression	[26]
Bile salt export pump (ABCB11)	OTRU7THO	ABCBB_HUMAN	Decreases Activity	[27]
Glucocorticoid receptor (NR3C1)	OTCI2YDI	GCR_HUMAN	Decreases Expression	[28]
ATP-binding cassette sub-family C member 3 (ABCC3)	OTC3IJV4	MRP3_HUMAN	Increases Expression	[29]
Interleukin-1 receptor-associated kinase-like 2 (IRAK2)	OT6Y1QZN	IRAK2_HUMAN	Decreases Expression	[30]
Nuclear receptor subfamily 1 group I member 2 (NR1I2)	OTC5U0N5	NR1I2_HUMAN	Increases Activity	[31]
T-cell surface glycoprotein CD4 (CD4)	OT7Z5LNF	CD4_HUMAN	Decreases Expression	[32]
Interleukin-6 (IL6)	OTUOSCCU	IL6_HUMAN	Decreases Secretion	[33]
Retinoblastoma-associated protein (RB1)	OTQJUJMZ	RB_HUMAN	Increases Activity	[34]
Progesterone receptor (PGR)	OT0FZ3QE	PRGR_HUMAN	Decreases Activity	[35]
Poly polymerase 1 (PARP1)	OT310QSG	PARP1_HUMAN	Increases Cleavage	[36]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Decreases Activity	[37]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[38]
Cyclin-A2 (CCNA2)	OTPHHYZJ	CCNA2_HUMAN	Decreases Expression	[39]
Brain-derived neurotrophic factor (BDNF)	OTLGH7EW	BDNF_HUMAN	Decreases Expression	[40]
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Increases Activity	[31]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Decreases Expression	[36]
Proliferation marker protein Ki-67 (MKI67)	OTA8N1QI	KI67_HUMAN	Decreases Expression	[41]
Cyclin-dependent kinase inhibitor 1B (CDKN1B)	OTNY5LLZ	CDN1B_HUMAN	Increases Expression	[42]
Tumor necrosis factor ligand superfamily member 6 (FASLG)	OTZARCHH	TNFL6_HUMAN	Increases Expression	[38]
Cathelicidin antimicrobial peptide (CAMP)	OT3Y8011	CAMP_HUMAN	Decreases Expression	[30]
Forkhead box protein L2 (FOXL2)	OTFRQUYL	FOXL2_HUMAN	Increases Expression	[42]
Neutrophil defensin 1 (DEFA1)	OT5N1B9B	DEF1_HUMAN	Decreases Expression	[30]
Neutrophil defensin 3 (DEFA3)	OTO3N8E1	DEF3_HUMAN	Decreases Expression	[30]
Transcription factor E2F1 (E2F1)	OTLKYBBC	E2F1_HUMAN	Decreases Expression	[39]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Increases Expression	[38]
Protein GREB1 (GREB1)	OTU6ZA26	GREB1_HUMAN	Increases Expression	[43]
Progesterone-induced-blocking factor 1 (PIBF1)	OTCBT1A1	PIBF1_HUMAN	Decreases Expression	[30]
Interleukin-1 receptor-associated kinase 4 (IRAK4)	OT9JTJWC	IRAK4_HUMAN	Decreases Expression	[30]
Toll-like receptor 7 (TLR7)	OT3HZV7Z	TLR7_HUMAN	Decreases Expression	[30]
Semaphorin-3B (SEMA3B)	OTCZCPMS	SEM3B_HUMAN	Increases Response To Substance	[44]
Semaphorin-3F (SEMA3F)	OTQFMS8S	SEM3F_HUMAN	Increases Response To Substance	[44]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
DD2	DC3SHVQ	DD2	Investigative	[45]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] Miconazole FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2449).
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2805).
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
• [7] Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos. 2008 Feb;36(2):339-48.
• [8] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [9] Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocr Res. 2004 Aug;30(3):387-94.
• [10] Ketoconazole and miconazole are antagonists of the human glucocorticoid receptor: consequences on the expression and function of the constitutive androstane receptor and the pregnane X receptor. Mol Pharmacol. 2006 Jul;70(1):329-39.
• [11] In vitro inhibitory effects of asiaticoside and madecassoside on human cytochrome P450. Toxicol In Vitro. 2011 Jun;25(4):890-6.
• [12] Direct stimulation of adenylyl cyclase 9 by the fungicide imidazole miconazole. Naunyn Schmiedebergs Arch Pharmacol. 2019 Apr;392(4):497-504. doi: 10.1007/s00210-018-01610-1. Epub 2019 Jan 3.
• [13] The classic azole antifungal drugs are highly potent endocrine disruptors in vitro inhibiting steroidogenic CYP enzymes at concentrations lower than therapeutic Cmax. Toxicology. 2019 Sep 1;425:152247. doi: 10.1016/j.tox.2019.152247. Epub 2019 Jul 19.
• [14] Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis. J Invest Dermatol. 2001 Dec;117(6):1635-46. doi: 10.1046/j.0022-202x.2001.01566.x.
• [15] Miconazole induces protective autophagy in bladder cancer cells. Environ Toxicol. 2021 Feb;36(2):185-193. doi: 10.1002/tox.23024. Epub 2020 Sep 27.
• [16] Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
• [17] Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
• [18] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [19] [Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro]. Zhonghua Wai Ke Za Zhi. 2006 Mar 15;44(6):382-5.
• [20] The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8.
• [21] Evaluation of strategies for the assessment of drug-drug interactions involving cytochrome P450 enzymes. Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):737-750.
• [22] Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica. 2006 Apr;36(4):287-99.
• [23] A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system. J Pharmacol Exp Ther. 2002 Oct;303(1):412-23.
• [24] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [25] Effect of the interaction between lipoxygenase pathway and progesterone on the regulation of hydroxysteroid 11-Beta dehydrogenase 2 in cultured human term placental trophoblasts. Biol Reprod. 2008 Mar;78(3):514-20.
• [26] Influence of progesterone on endometrial nitric oxide synthase expression. Fertil Steril. 2009 May;91(5 Suppl):2157-62.
• [27] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [28] Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression. Toxicol Appl Pharmacol. 2014 Oct 1;280(1):138-48.
• [29] Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos. 2003 Nov;31(11):1296-9. doi: 10.1124/dmd.31.11.1296.
• [30] Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone. Leuk Lymphoma. 2007 Aug;48(8):1610-7. doi: 10.1080/10428190701471999.
• [31] Improved assays for xenosensor activation based on reverse transfection. Toxicol In Vitro. 2015 Oct;29(7):1759-65. doi: 10.1016/j.tiv.2015.07.011. Epub 2015 Jul 14.
• [32] Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells. Immunol Lett. 2010 Jun 15;131(1):24-32. doi: 10.1016/j.imlet.2010.03.009. Epub 2010 Apr 2.
• [33] [Regulatory effects of mifepristone and progesterone on the secretion of interleukin-6 by cultured eutopic and etopic endometrial cells]. Zhonghua Fu Chan Ke Za Zhi. 2001 Oct;36(10):603-5.
• [34] Mifepristone induces growth arrest, caspase activation, and apoptosis of estrogen receptor-expressing, antiestrogen-resistant breast cancer cells. Clin Cancer Res. 2004 Aug 1;10(15):5215-25. doi: 10.1158/1078-0432.CCR-03-0637.
• [35] The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Int J Oncol. 2005 Jun;26(6):1507-15.
• [36] Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3. Oncol Rep. 2006 Apr;15(4):743-8.
• [37] Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4.
• [38] Effect of mifepristone on proliferation and apoptosis of Ishikawa endometrial adenocarcinoma cells. Fertil Steril. 2005 Jul;84(1):202-11. doi: 10.1016/j.fertnstert.2005.01.126.
• [39] Mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res. 2007 Jun 1;13(11):3370-9. doi: 10.1158/1078-0432.CCR-07-0164.
• [40] Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Aust N Z J Psychiatry. 2007 Apr;41(4):321-6. doi: 10.1080/00048670701213211.
• [41] The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology. Hum Reprod. 2008 Sep;23(9):2072-9. doi: 10.1093/humrep/den228. Epub 2008 Jun 24.
• [42] MiR-17-5p/FOXL2/CDKN1B signal programming in oocytes mediates transgenerational inheritance of diminished ovarian reserve in female offspring rats induced by prenatal dexamethasone exposure. Cell Biol Toxicol. 2023 Jun;39(3):867-883. doi: 10.1007/s10565-021-09645-6. Epub 2021 Sep 19.
• [43] A Gene Expression Biomarker Identifies Chemical Modulators of Estrogen Receptor in an MCF-7 Microarray Compendium. Chem Res Toxicol. 2021 Feb 15;34(2):313-329. doi: 10.1021/acs.chemrestox.0c00243. Epub 2021 Jan 6.
• [44] Progesterone and 1,25-dihydroxyvitamin D? inhibit endometrial cancer cell growth by upregulating semaphorin 3B and semaphorin 3F. Mol Cancer Res. 2011 Nov;9(11):1479-92. doi: 10.1158/1541-7786.MCR-11-0213. Epub 2011 Sep 20.
• [45] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.